The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients
Eur J Intern Med
.
2022 Jul:101:124-127.
doi: 10.1016/j.ejim.2022.03.015.
Epub 2022 Mar 16.
Authors
F Calabretta
1
,
P S Preti
2
,
M Russo
2
,
C Klersy
3
,
A Di Sabatino
2
Affiliations
1
Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. Electronic address:
[email protected]
.
2
Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
3
Clinical Epidemiology and Biometry Service. IRCCS Policlinico San Matteo Foundation. Pavia, Italy.
PMID:
35307245
PMCID:
PMC8923898
DOI:
10.1016/j.ejim.2022.03.015
No abstract available
Keywords:
Covid-19; Enoxaparin; Myocardial infarction; Venous thrombosis.
Publication types
Letter
MeSH terms
Anticoagulants / therapeutic use
COVID-19*
Enoxaparin
Heparin* / therapeutic use
Hospitals
Humans
Substances
Anticoagulants
Enoxaparin
Heparin